NOVOMEDLINK™
  1. Diabetes Care

    GlucaGen® HypoKit®

    (glucagon [rDNA Origin] for injection)

  2. Levemir®

    (insulin detemir [rDNA origin] injection)

  3. NovoLog®

    (Insulin aspart [rDNA origin] injection)

  4. NovoLog® Mix 70/30

    (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin])

  5. Victoza®

    (liraglutide [rDNA origin] injection)

  6. Hormone Therapy

    Activella®

    (estradiol/norethindrone acetate tablets)

  7. Vagifem®

    (estradiol vaginal tablets)

  8. Growth Hormone

    Norditropin®

    (somatropin (rDNA origin) injection)

  9. Hemostasis

    NovoSeven®

    (Coagulation Factor VIIa [Recombinant])

  10. NovoSeven® RT

    Coagulation Factor VIIa (Recombinant) Room
    Temperature Stable

Access to NovoSeven® RT

Order by Phone

Call 1-877-NOVO-777, Select Option 2
For product orders, operators are available 24 hours a day, 7 days a week. Call 1-877-NOVO-777 and select option 2.

Contact a Distributor

To make stocking NovoSeven® RT easier, the following is a list of vendors who distribute NovoSeven® RT. Simply contact the vendor directly to place your order.

Calculate How Much NovoSeven® RT to Order

NovoSeven® RT should be given as early as possible after the start of a bleeding episode.

The recommended initial dose for patients with hemophilia A or B with inhibitors, administered by intravenous bolus injection, is 90 mcg/kg body weight.

The recommended dose range in congenitally FVII-deficient patients is 15-30 mcg/kg body weight.

Recommended dosing for acquired hemophilia is 70-90 mcg/kg every 2-3 hours until hemostasis is achieved.

Following the initial dose of NovoSeven® RT, further injections may be repeated. The duration of treatment and the interval between injections will vary with the severity of the bleed.

Use our online dosing calculator.

New Customer Credit Application

You'll need to print out this form. Fill it out and have it ready when you call Novo Nordisk to order NovoSeven® RT.

Download PDF

You will need Adobe Acrobat Reader to open this file. For a free version, please click here

  1. NovoSeven® RT Coagulation Factor VIIa (Recombinant) Room Temperature Stable Indications and Usage

    NovoSeven® RT is indicated for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; treatment of bleeding episodes in patients with congenital FVII deficiency and prevention of bleeding in surgical interventions or invasive procedures in patients with congenital FVII deficiency.

    NovoSeven® RT Important Safety Information

    • The most common adverse events of NovoSeven® RT therapy are pyrexia, hemorrhage, injection site reaction, arthralgia, headache, hypertension, hypotension, nausea, vomiting, pain, edema, and rash. The most serious adverse events observed during NovoSeven® RT therapy are thrombotic events.
    • Patients with disseminated intravascular coagulation (DIC), advanced atherosclerotic disease, crush injury, septicemia, or concomitant treatment with activated or nonactivated prothrombin complex concentrates (aPCCs/PCCs) may have a potential risk of developing thrombotic events in association with NovoSeven® RT treatment.
    • Use with caution in patients with known hypersensitivity to NovoSeven® RT, its components, or mouse, hamster, or bovine proteins.
    • Serious adverse events that may have been related to the use of NovoSeven® RT in acquired hemophilia included thrombotic serious adverse events and death.
    • Serious adverse events that may have been related to the use of NovoSeven® RT occurred in 14 of 298 patients with hemophilia A or B with inhibitors in the initial clinical program.
    • Development of antibodies against FVII has been reported in FVII-deficient patients after treatment with NovoSeven® RT. These patients had previously been treated with human plasma and/or plasma-derived FVII. Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity before and after administration of NovoSeven® RT.
    • Concomitant use of NovoSeven® RT with other formulations of NovoSeven® is not recommended due to potential dosing errors based on different concentrations.

    Please see Prescribing Information.

  2. NovoSeven® Coagulation Factor VIIa (Recombinant) Indications and Usage

    For the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; treatment of bleeding episodes in patients with congenital Factor VII deficiency and prevention of bleeding in surgical interventions or invasive procedures in patients with congenital FVII deficiency.

    (Acquired only) For the treatment of bleeding episodes in patients with acquired hemophilia. For the prevention of bleeding in surgical interventions or invasive procedures in patients with acquired hemophilia.

    NovoSeven® Important Safety Information

    • Most common adverse events: pyrexia, hemorrhage, injection site reaction, arthralgia, headache, hypertension, hypotension, nausea, vomiting, pain, edema, and rash.
    • Patients with disseminated intravascular coagulation (DIC), advanced atherosclerotic disease, crush injury, septicemia, or concomitant treatment with activated or nonactivated prothrombin complex concentrates (aPCCs/PCCs) may have a potential risk of developing thrombotic events in association with NovoSeven treatment.
    • Contraindicated in patients with known hypersensitivity to NovoSeven, its components, or mouse, hamster, or bovine proteins.
    • Serious adverse events that may or may not have been related to the use of NovoSeven in acquired hemophilia (10 of 139 patients in the compassionate use program, HTRS registry, and the published literature) may include thrombotic serious adverse events and death.
    • Serious adverse events that may or may not have been related to the use of NovoSeven occurred in 14 of 298 patients with hemophilia A or B with inhibitors in the initial clinical program.
    • Development of antibodies against FVII has been reported in FVII deficient patients after treatment with NovoSeven. These patients had previously been treated with human plasma and/or plasma-derived FVII.

    Please see Prescribing Information.

GlucaGen®, HypoKit®, Levemir®, and NovoLog® are registered trademarks and NovoMedLink™ is a trademark of Novo Nordisk A/S. Norditropin® and NovoSeven® are registered trademarks and SevenSECURE™ is a trademark of Novo Nordisk Health Care AG. Activella® and Vagifem® are registered trademarks of Novo Nordisk FemCare AG.